Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors

NCT00482521 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00482521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00482521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2012
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific